The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Visninger
administrator
administrator
07/18/23

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

  • Kategori

Vis mere

0 Kommentarer Sorter efter

Ingen kommentarer fundet

Facebook kommentarer

Nรฆste